Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Change in Accured Expenses: 2020-2023

Historic Change in Accured Expenses for Candel Therapeutics (CADL) over the last 3 years, with Dec 2023 value amounting to $946,000.

  • Candel Therapeutics' Change in Accured Expenses rose 117.47% to $946,000 in Q4 2023 from the same period last year, while for Dec 2023 it was -$301,000, marking a year-over-year decrease of 123.79%. This contributed to the annual value of $757,000 for FY2024, which is 351.50% up from last year.
  • According to the latest figures from Q4 2023, Candel Therapeutics' Change in Accured Expenses is $946,000, which was up 1,212.94% from -$85,000 recorded in Q3 2023.
  • Over the past 5 years, Candel Therapeutics' Change in Accured Expenses peaked at $1.4 million during Q4 2020, and registered a low of -$1.8 million during Q1 2023.
  • Over the past 3 years, Candel Therapeutics' median Change in Accured Expenses value was $310,500 (recorded in 2022), while the average stood at $105,083.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first spiked by 510.61% in 2021, then tumbled by 2,088.89% in 2023.
  • Over the past 4 years, Candel Therapeutics' Change in Accured Expenses (Quarterly) stood at $1.4 million in 2020, then plummeted by 48.24% to $719,000 in 2021, then tumbled by 39.50% to $435,000 in 2022, then soared by 117.47% to $946,000 in 2023.
  • Its last three reported values are $946,000 in Q4 2023, -$85,000 for Q3 2023, and $628,000 during Q2 2023.